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Quantitative comparison of 
different iron forms in the temporal 
cortex of Alzheimer patients and 
control subjects
Marjolein Bulk1,2,3, Louise van der Weerd  1,2, Wico Breimer4, Nikita Lebedev4, Andrew 
Webb1, Jelle J. Goeman5, Roberta J. Ward6, Martina Huber4, Tjerk H. Oosterkamp4 &  
Lucia Bossoni1,4
We present a quantitative study of different molecular iron forms found in the temporal cortex of 
Alzheimer (AD) patients. Applying the methodology we developed in our previous work, we quantify 
the concentrations of non-heme Fe(III) by Electron Paramagnetic Resonance (EPR), magnetite/
maghemite and ferrihydrite by SQUID magnetometry, together with the MRI transverse relaxation rate 
⁎(R )2 , to obtain a systematic view of molecular iron in the temporal cortex. Significantly higher values of ⁎R2, a larger concentration of ferrihydrite, and a larger magnetic moment of magnetite/maghemite 
particles are found in the brain of AD patients. Moreover, we found correlations between the 
concentration of the iron detected by EPR, the concentration of the ferrihydrite mineral and the 
average iron loading of ferritin. We discuss these findings in the framework of iron dis-homeostasis, 
which has been proposed to occur in the brain of AD patients.
Iron is an essential component of many enzymes and proteins that participate in a variety of biological functions 
in the brain, such as neurotransmitter synthesis and myelination of neurons1. Increases in the iron content of spe-
cific brain regions were identified in many neurodegenerative diseases, e.g. Alzheimer’s Disease (AD), Parkinson’s 
Disease, and Friederich Ataxia2–6. In AD, which is clinically characterised by progressive dementia, increased iron 
content in the temporal, parietal and frontal lobes has been reported7,8. In the presence of the pathological hall-
marks of AD, iron is accumulated within and around the amyloid-beta plaques (Aβ) and neurofibrillary tangles3,9, 
mostly as ferrihydrite inside ferritin, hemosiderin, and magnetite.
The co-localization of iron with Aβ has been proposed to constitute a major source of toxicity. Indeed, in vitro, 
Aβ has been shown to convert ferric iron (Fe(III)) to ferrous (Fe(II)) iron10,11, which can act as a catalyst for the 
Fenton reaction to generate toxic free radicals, which in turn result in oxidative stress.
Mineralized forms of iron, other than ferrihydrite, are found inside12,13 and outside ferritin14,15. For example, 
it has been shown that magnetite and wüstite are both present in the AD brain15. This is of importance as such 
species possess Fe(II), which is associated with toxicity. Although these nanoparticles may be present in low 
concentrations16, if they are larger than 40–50 nm in diameter, they carry a permanent magnetic moment at room 
temperature14,15,17, which can significantly affect the proton Nuclear Magnetic Resonance Imaging (MRI) signal, 
thus allowing indirect imaging of iron18–20.
The magnetic moment of iron/iron nanoparticles dephases the proton spins of close-by diffusing water mole-
cules, leading to the shortening of the endogenous spin-spin relaxation times (T2 and ⁎T2)18,21–23. Therefore, local 
iron accumulation is observed as hypointense areas on T2 and ⁎T2-weighted multi-echo MRI sequences. In vivo 
and post-mortem MRI have shown that in AD, cortical iron can be visualized as bands or foci of signal loss24,25. In 
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addition, elevated tissue ferritin levels are often associated with low values of ⁎T2  in AD patients26,27. 
Susceptibility-weighted imaging (SWI)18 and quantitative susceptibility mapping (QSM)28,29 are methods based 
on the correspondence between measured phase and local magnetic field, and were employed to assess brain 
iron30,31. However, the results from SWI analyses depend on the particular orientation, geometry and position of 
the dipolar field source, and both SWI and QSM do not differentiate between molecular forms of iron. Moreover, 
although a positive linear correlation between MRI relaxation times and tissue iron has been shown27,30,32–35, most 
of the MRI studies refer to “iron” in very general terms, while only a few studies have investigated correlations 
between MRI relaxation times and specific molecular iron forms, mostly as ferritin-stored iron26,27,36. Non-heme 
iron types are diverse and contribute differently to the MRI relaxation times, via their different magnetic 
moments37. Indeed, there are many other potential confounding factors in using susceptibility for absolute iron 
quantification, for example, a lower cell water content, abrupt susceptibility changes18, changes in myelination36,38 
and co-localization with Aβ39.
In order to provide a systematic and quantitative view of different molecular/mineral iron forms in brain tis-
sue, we recently developed a combination of methods40, by which we can quantify: (i) non-heme rhombic Fe(III); 
(ii) ferrihydrite (Fe2O3 ⋅ 0.5H2O) and (iii) magnetite/maghemite (Fe3O4/γ−Fe2O3). In contrast to previous studies, 
in which only one iron-oxide species was quantified, here we present a broad overview of iron forms obtained 
from a brain region where elevated iron concentration is found in AD. Furthermore, in this present work, we 
show how to derive the magnetic moment of magnetite and the iron loading of ferritin from magnetometry data. 
We apply the methodology described earlier40 and we complement our set of techniques with MRI, which we 
performed on the same tissue sample used for the other experimental techniques.
In the present study, we have focussed on the middle temporal gyrus, since the temporal lobe is the most 
affected in terms of AD pathological hallmarks (Aβ and τ-tangles), and is the earliest cortical region to develop 
AD pathology. Additionally, there is evidence that both AD pathological hallmarks correlate with the amount of 
iron and myelin accumulation in the cortex41.
Finally, we applied our methodology to a substantially large number of samples (22 AD patients and 14 con-
trols) and we found significant differences in the iron forms between AD and controls. Furthermore, we show 
correlations, which were previously undetected, among different iron forms.
Materials and Methods
All measurements and raw data analysis were carried out blind to diagnosis.
MRI experiments. Formalin-fixed tissue samples of the temporal middle gyrus were obtained from the 
Netherlands Brain Bank (NBB). Diagnosis of AD was confirmed by neuropathological examination in agree-
ment with the guidelines of the ethics committee of the LUMC. Patient anonymity was strictly maintained. All 
tissue samples were handled in a coded fashion, according to Dutch national ethical guidelines (Code for Proper 
Secondary Use of Human Tissue, Dutch Federation of Medical Scientific Societies).
Before the Nuclear Magnetic Resonance Imaging (MRI) experiment, the tissue was washed in phosphate 
buffered saline (PBS) for 24 h, to remove residual formalin and partially restore the physiological proton relaxa-
tion times to those before fixation. Finally, the tissue was inserted into a plastic tube, immersed in a proton-free 
solution (fomblin), and kept in place by gauze.
MRI scans were performed on a 7T horizontal bore Bruker MRI system equipped with a 23 mm receiver coil 
and Paravision 5.1 imaging software (Bruker Biospin, Ettlingen, Germany).
High-spatial-resolution MRI scans were obtained with a three-dimensional ⁎T2 -weighted Multi-Gradient-Echo 
sequence. Repetition time TR = 75 ms, echo spacing TE = 12.5, 23.3, 33.9 and 44.6 ms, 100 μm isotropic resolu-
tion, flip angle = 15 degrees, 10 averages, 140 × 240 pixels. The complete imaging protocol had a total duration of 
3.5 hours. The ⁎R2  rate was obtained after fitting the signal decay with the following expression:
= − ⋅
⁎
y Ae (1)TE R2
where A is a prefactor (See Supplementary Information for details on the quality of the fit). By inspecting the MRI 
scans of the samples from AD patients, a diffuse hypointense band, as described previously19,25, was observed in 
the grey matter (see Fig. 1A). The region of interest (ROI) selection was guided by the MRI scan: the ROI included 
all cortical layers in an area where the diffuse hypointense band was observed. In the absence of the diffuse 
hypointense band, an ROI was selected including all cortical layers. The median ⁎R2 of this ROI was calculated for 
each patient sample. The median was chosen instead of the mean since it was more stable with respect to the ROI 
selection. Analysis of the MRI data was performed with Matlab 2016.
EPR experiments. A section of approximately 10–20 mg was dissected from the brain tissue with a ceramic 
scalpel, and prepared for the Electron Paramagnetic Resonance (EPR) study. Material from the same anatomical 
region was taken from the control subjects, for comparison. The tissue section was chosen to colocalize with the 
selected ROI on the MRI scan. EPR was performed with a 9 GHz spectrometer, at 12 K, according to the method 
presented earlier40. The continuous wave (cw) EPR measurements were performed using an ELEXSYS E680 spec-
trometer (Bruker, Rheinstetten, Germany) equipped with a rectangular cavity. The microwave frequency was 
9.4859 GHz, modulation frequency 100 kHz, power attenuation 20 dB, receiver gain 60 dB and modulation ampli-
tude 6 Gpp. The accumulation time was 20 min. per spectrum. The concentration of Fe(III) (Fig. 1B) was deter-
mined for each patient by taking the second integral of the simulated signal, and by comparing it to the second 
integral of the reference sample (Fe-EDTA) of known concentration. All raw data with simulations are shown in 
the Supplementary Information. Data fitting to the spin Hamiltonian was performed with the EasySpin toolbox42. 
The spin Hamiltonian used for the fitting was typical for Fe(III), in the high-spin state:
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where g is the Landé factor, μB the Bohr magneton, B is the applied field and S the spin operator. The two final 
terms represent the zero-field splitting, where D is the axial splitting, and E the rhombic splitting. The EPR spec-
tra were fitted with the following parameters: S = 5/2, D = 20.96 GHz, E/D = 0.3324, g = [1.83, 1.998, 2.0151], 
gstrain = [0.574, 0.129, 0.0197]. More details on the spin Hamiltonian can be found elsewhere40.
SQUID experiments. Subsequent to the EPR experiments, an additional tissue sample containing only/
mostly grey matter adjacent to the tissue block used for MRI, was resected. This tissue sample was freeze-dried, 
pelleted, and studied by a Superconducting Quantum Interference Device (SQUID) magnetometer (MPMS). 
Isothermal Residual Magnetization (IRM) curves were measured at 100 K and 5 K40. We note that SQUID mag-
netometry is very sensitive for measuring magnetic impurities diluted in a non-magnetic host. However, one 
needs to make sure that the sample holder does not contain any fast-saturating component and that the field is 
zero and stable on the time-scale of the measurement. In this study, a Reciprocating Sample Option (RSO) probe, 
with sensitivity of 1 × 10−8 emu at low field (i.e. 0–2.5 T) was used. Despite the high sensitivity of the RSO, a few 
samples showed low signal-to-noise ratio (SNR) at 100 K. Those data were discarded from the analysis: we chose 
to set to zero the concentration of magnetite/maghemite of those samples whose 100 K-signal was close to the 
detection limit of the instrument, and the magnetic moment of these samples was discarded in the statistical anal-
ysis (see Results section). However, as shown in the Supplementary Information, many samples had a measurable 
signal and an SNR larger than 4. On the other hand, the 5 K data showed a signal that was much larger than the 
sensitivity of the instrument, for all samples.
The measured magnetic moment was divided by the dry mass of the sample, and the obtained IRM curve was 
fitted to the Langevin equation:
= − +IRM x M f x x B[ ] [coth( ) 1/ ] (3)s
where =
μ
x
H
k T
p
B
, H is the magnetic field, μp is the average magnetic moment of the particles, kB is the Boltzmann 
constant, T is the temperature, Ms is the saturation magnetization, f is the mass fraction of magnetic particles and 
B is a constant which takes into account residual fields. Both the 100 K and the 5 K data were fitted to the same 
Langevin equation (see Supplementary Information). IRM measured at 100 K was used to obtain the concentra-
tion of magnetite/maghemite nanoparticles and their magnetic moment, while the non-saturating data at 5 K 
(Fig. 1C) were used to derive the concentration of ferrihydrite37,43,44. In the fit, the temperature and the saturation 
magnetization were fixed to the experimental condition and to the literature data, respectively. For magnetite 
(maghemite), different values of saturation magnetization are reported, ranging from 98 (76) emu/g for bulk 
material45, to 72 emu/g for particles of size 30–40 nm46, to lower values for 5 nm particles17. Magnetite/maghemite 
particles with a minimum particle-size of 25–35 nm have their magnetic moment blocked at approximately 
100 K40, therefore we used Ms = 84 emu/g, in the above equation as a reference value. As far as ferrihydrite is con-
cerned, a saturation magnetization of Ms = 0.62 emu/g is typically accepted43,47.
The fraction f of magnetic material, the magnetic moment μp, and the background constant B were obtained 
from the fit of each patient’s curve (see Supplementary Information). For ferrihydrite, the magnetic moment 
is related to the number of iron atoms stored within the core of ferritin, also known as the loading factor (LF). 
According to Néel’s theory of superparamagnetism, the relation between the two is given by48:
μ μ= . αLF5 92 (4)p B
Figure 1. Example of raw data obtained from this study. Panel A shows the MRI scan (third echo of the Multi-
Gradient-Echo scan). Some dark bands are observable in the grey matter, and indicated by white arrows. 
Panel B shows the smoothed EPR spectrum obtained from the same subject. Panel C illustrates the IRM data 
measured with the SQUID magnetometer at 100 K (red curve), showing the presence of magnetite/maghemite, 
and 5 K (blue curve), attributed to the presence of ferritin.
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where α = 0.5−0.6, and 5.92 μB corresponds to the ionic magnetic moment of Fe(III). Dividing LF by the maxi-
mum number of iron ions that ferritin can accommodate, i.e. 4500, we obtained the ferritin loading ratio (FLR), 
here expressed as a percentage, for clarity. Similarly, the magnetic moment of magnetite/maghemite is propor-
tional to the volume of the particles. We will return to this concept in the following paragraphs.
Statistical analysis. Statistical analysis was performed using R-Studio (R version 3.3.2). The packages used 
were ggplot249, ggally50, stats51, outliers52, corrplot53 and ppcor54. All data sets were tested for normality with the 
methods of visual inspection, q-q plot and normal Shapiro test. Outlier detection was done by visual inspection, 
q-q plot and Chi-square test. Data points were excluded only when the visual inspection and the formal tests 
agreed with each other. If required, normality was restored upon applying a log10-transformation: Fe(III) con-
centrations have been log10-transformed. Fe3O4/γ−Fe2O3 (magnetite/maghemite) data have been transformed 
with the following: log10(x + C), where x is the particle concentration, and C = 100. Hypothesis testing (t-test) 
was performed on the transformed data. Differences in mean were considered significant when the p-value was 
smaller than 0.05. The variance of the distribution was also tested using the Brown-Forsythe Levene-type test, 
based on the absolute deviations from the median.
Spearman’s correlation coefficients for all pairs of iron forms were calculated on non-transformed data. A 
formal comparison between the inter-group correlations coefficients was performed by Fisher-transforming the 
correlations coefficients (ρ) and then calculating their studentized difference as a basis for a two-tailed z-test. In 
more detail, we transformed ρ into z-scores, per group (i)55:
ρ ρ= + − .zr 1/2 ln((1 )/(1 )) (5)i i i
Afterward, the difference in z-scores was calculated, with the following expression:
=
−
− + −
z zr zr
N N1/( 3) 1/( 3)
,
(6)
diff
2 1
1 2
where Ni is the number of individuals used for the calculation, and the index i = 1, 2 refers to the group (AD or 
control). This difference was used as a basis for a two-tailed z-test.
For those pairs of variables showing a significant correlation, a partial correlation test was carried out to 
exclude spurious correlations. In this last test, AD and control groups were pooled to increase the statistical 
power, in the case that the correlation comparison test was not significant.
Sample preparation. All details of sample preparation and handling are described in our previous work40.
In this study, formalin-fixed material has been used. The effect of formalin fixation on the chemical state of 
iron is the subject of debate within the literature, with very different conclusions reached by different research 
groups56. Although frozen brain material is probably the best starting material when it comes to the quantifica-
tion of metals, working with frozen brain material is not a feasible option when a comparison among different 
techniques performed on the same piece of tissue is carried out. Most importantly, MRI cannot be easily done on 
frozen tissue, due to the very short T2 values of frozen tissue as well as the long duration of high-resolution scans 
(typically of a few hours), which may affect the integrity of the tissue.
Finally, from a methodological point-of-view, it is worth noting that our results have been obtained without 
the need of chemical purification of the different iron forms, nor by performing any biochemical assay test, being 
based purely on the magnetic properties of the tissue.
Results
Table 1 reports the characteristics of the individuals and the concentration of the measured iron forms, as means 
and standard deviations. P-values obtained from the t-test (mean comparison) are also reported. No significant 
differences were found in age or gender between the AD and control group.
The value of ⁎R2  was significantly higher in the AD group vs. the control group (p = 0.008). Ferrihydrite con-
centration was significantly higher in the AD group (p = 0.007), while the ferritin loading ratio (FLR) was not 
significantly different between groups (p = 0.362). The concentration of magnetite/maghemite (note that the 
magnetite/maghemite will be named “magnetite” in the figures, for simplicity) nanoparticles was not different 
between the two groups (p = 0.878), while the average magnetic moment of the particles was larger in the AD 
group (p = 0.002). Finally, the Fe(III) concentration was not significantly different between groups (p = 0.125).
The extent to which the variance between the two groups is identical was also independently tested. We found 
that only the distribution of ferrihydrite concentration showed a significantly different variance between AD and 
control group (p = 0.026). The results of this test are reported in the Supplementary Information.
Subsequently, the individuals were stratified by their Braak Stage: control individuals with Braak Stage equal 
to or lower than 3 were grouped together. We found that those iron forms showing a significant inter-group dif-
ference in the mean, i.e. ⁎R2  values, ferrihydrite concentration and magnetite/maghemite magnetic moment, also 
showed a positive trend with increasing Braak Stage (Fig. 2), although no formal test was done due to the limited 
number of samples in each group.
We further carried out a correlation study to investigate associations among the measured iron forms, and 
between iron and ⁎R2  values. Figure 3 represents the correlation matrices (named correlogram hereafter) for all 
measured iron forms, in the form of ellipses, the eccentricity and intensity of which is equal to the Spearman’s 
correlation coefficient between the variables reported on the axes.
Our initial findings indicate that some iron forms strongly correlate with each other. In particular, Fe(III) 
concentration positively associates with the FLR (Spearman’s ρ = 0.825 for the AD patients, and 0.865 for the con-
trol subjects) and negatively with ferrihydrite concentration (ρ = −0.629 for the AD, and −0.908 for the control 
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group). Additionally, ferrihydrite concentration correlates negatively with the FLR (ρ = −0.729 for the AD, and 
−0.935 for the control group), and the magnetite concentration associates positively with ferrihydrite concentra-
tion (ρ = 0.474) only for the AD group. The rest of the correlations were not significant.
When we compared the correlation coefficients between the two groups (AD vs. controls), we found that they 
were not significantly different, although the ferrihydrite-Fe(III) and the FLR-ferrihydrite pairs were associated 
with a rather small p-value (0.076 and 0.079, respectively) (see Supplementary Information, Table SII).
Since three variables were mutually correlated, we performed a partial correlation test to assess the correlation 
between two variables, while controlling for the effect of the third one. The results of the partial correlation are 
reported in Table 2. Note that during this test, the AD and control data were pooled, in the light of the results of 
the correlation comparison test. 
The partial correlation test shows that the negative correlation found between Fe(III) and ferrihydrite may be 
spurious, and can be explained by the effect of the FLR variable.
Discussion
In this study, we seek to identify the differences in iron forms in the temporal cortex of Alzheimer patients and age- 
and gender-matched controls. A unique combination of techniques40 enables us to differentiate these iron forms to a 
much larger degree than previously possible. One brain region affected by Alzheimer’s disease, the temporal cortex, 
was selected from different AD patients and control subjects, and an extensive statistical analysis was employed. 
The temporal lobe was chosen since it is the most affected region in terms of AD pathological hallmarks (Aβ and 
τ-tangles), as mentioned earlier. In order to investigate different iron forms on the same sample, experiments were 
performed by different techniques, which required the use of formalin-fixed tissue (see Materials and Methods).
In the following discussion, we first analyse each iron form separately, and then summarize the statistically 
relevant conclusions which we divide into correlations common to both groups, and differences between groups. 
Additionally, we compare these findings with MRI ⁎R2 values obtained from the very same anatomical region.
The g′ = 4.3 EPR band was found in every measured sample. This signal has been often ascribed in literature 
to non-heme high-spin Fe(III) in a system of rhombic symmetry57,58. We exclude the possibility that this signal 
is due to sample environment contamination since it was absent when either the empty cavity or a test tube 
containing the fixating solution were studied. The signal can be ascribed to the ms = ±3/2 Kramers doublet of 
rhombic S = 5/2 systems and it is not fully understood59. This iron form has taken different names in the litera-
ture, including mono-nuclear “spurious” iron, labile iron, iron bound to complexes of low molecular weight, and 
non-transferrin bound iron (NTBI)1,60. It is beyond the scope of this work to identify the specific ligand environ-
ment responsible for the observed signal. However, in our previous work, we already discussed why this signal is 
not ascribable to transferrin40, the main iron transporter protein61.
The concentration of Fe(III) in the temporal cortex found in this study ranged between 1.58 and 14.95 μg/g 
(wet weight), equivalent to 28.3 μM and 267.6 μM respectively, while the concentration of intracellular labile iron 
pool should fall in the 0.2–10 μM range, as assessed by several studies, which used EPR or fluorescent probes to 
quantify labile iron in homogenized tissue, cells, and ferritin solution62–66. A quantitative comparison between 
the iron concentration obtained in our study versus the commonly accepted values suggests that our g′ = 4.3 
band cannot exclusively be attributed to the labile iron pool. On the other hand, here we speculate that the signal 
can originate from a site that is part of the ferritin iron core, but does not show superparamagnetic properties. 
Indeed, this signal is often found in studies of the incorporation of iron into mammalian and bacterial ferrit-
ins67,68. Additionally, from a magnetic viewpoint, this iron could be present on the outer surface of the core, thus 
experiencing a smaller Weiss molecular field than those atoms strongly bound to the core. This may result in a 
lower Néel temperature, as already proposed69, and the effective paramagnetic behaviour demonstrable by the 
g′ = 4.3 signal40.
The ferrihydrite concentrations assayed in the present study (range: 25.8–730.7 μg/g) are in agreement with 
those reported earlier for ferritin18. Ferrihydrite concentration provides a measure of the ferritin-bound iron in 
AD (n = 22) Control (n = 14) p-value mean test
Characteristics
Male 8 4 0.248
Female 14 10 0.414
Mean age (range, yrs) 76.7 (43–96) 79.8 (64–91) 0.673
Experimental Results
⁎R2 (mean ± sd, ms−1) 0.033 ± 0.005 0.028 ± 0.004 0.008
Fe(III) (mean ± sd, μg/gww) 6.74 ± 3.48 5.29 ± 3.66 0.125
Fe3O4/γ−Fe2O3 (mean ± sd, ng/gdw) 118.83 ± 125.87 121.03 ± 123.11 0.878
Fe2O3 • 0.5H2O (mean ± sd, μg/gdw) 381.12 ± 178.97 240.84 ± 98.02 0.007
Table 1. Summary of sample characteristics and experimental results. A chi-square test was used to assess 
differences in gender between AD and control group. A Mann-Whitney U test was used to assess differences 
in age between AD and control group. Student’s t-test was performed to test differences in the means of the 
measured iron concentrations. Statistical tests were repeated with and without the presence of the outliers, and 
the same conclusion about the significance of the test was reached. The index dw refers to dry weight, and ww 
refers to wet weight.
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the tissue, while its magnetic moment is related to the iron loading of the protein. Typically, 4500 iron atoms per 
protein are considered to be the maximum which the core can store in vitro. However, in vivo loading may be 
lower: some studies reported a loading of 1500 atoms in vivo70,71, corresponding to roughly 33% of the protein 
capacity. Other findings show that, when ferritin is fractionated by density gradient centrifugation, the full range 
Figure 2. Visual representation of the iron forms grouped by Braak Stage. Each plot represents the 
concentration/magnetic property of the different iron forms grouped by the Braak Stage-number (outliers have 
been removed). All controls with Braak Stage equal to 3 or lower have been grouped in the variable “Braak Stage 3”. 
The AD patients have Braak Stage varying from 4 to 6. The μ symbol refers to the magnetic moment of the 
magnetite particle. For missing data in the ‘Magnetite μ′ variable, please see Materials and Methods.
Figure 3. Correlogram of the iron forms measured in this study and grouped by diagnosis. The ellipse 
eccentricity and color intensity are proportional to the Spearman’s correlation coefficient for a specific pair of 
iron forms (see also scale bar at the bottom). Left panel refers to the control group (N = 11, after outliers were 
removed as explained in the Materials and Methods section) while the right panel refers to the patients group 
(N = 18, after outlier removal). Correlograms which are not statistically significant, i.e. p-value > 0.05, are 
crossed. For those correlograms with p-value < 0.05, the correlation coefficient is reported in the respective 
squares. Letters are used to facilitate the comparison between pairs of variables.
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of ferritins, from native apoferritin to full ferritin, is found72,73. Our control subjects display an FLR ≤50% (the 
percentage refers to a maximum loading of 4500 atoms), while the AD patients display larger ferritin filling ratios, 
although this difference is not statistically significant.
Another mineralized iron form we were able to detect is magnetite/maghemite. Our IRM measurements are 
not able to disentangle magnetite and its oxidation product, maghemite. The concentration of magnetite/magh-
emite assayed (range: 0–418.4 ng/g) and the particles’ size that we previously estimated40 are within the range 
reported by others for magnetite in the frontal and temporal lobe15,16, although here we are sensitive to larger 
particles than in previous studies (see Materials and Methods). The magnetic moment (μ) of these particles is a 
measure of their volume. We point out that, given the large magnetic moment associated with these particles, i.e. 
larger than 100 μB for ferrihydrite and 1000 μB for magnetite/maghemite, this study suggests that MRI could be 
employed to selectively identify them in the brain of patients with AD.
In the following, we discuss the differences in the above-described iron forms between AD and control sub-
jects. From Fig. 4, we observe that ferrihydrite levels, magnetite/maghemite magnetic moment and ⁎R2 values are 
elevated in the temporal cortex of AD patients. The same iron forms show a positive trend with the Braak Stage 
(Fig. 2), which describes the distribution pattern of neurofibrillary changes74 and reflects the clinical progression 
of AD. This is in agreement with the work of Van Duijn et al., who recently showed a correlation between iron 
accumulation in the frontal cortex, the amount of Aβ and τ pathology41 and the Braak Stage.
The increase of ferrihydrite levels in the absence of an increase in the average FLR confirms earlier studies, 
suggesting a local accumulation of iron in the brain of AD patients2 and a higher expression of ferritin protein71. 
Given the recent observation that ferritin levels in the cerebrospinal fluid and in the plasma are associated with 
cognitive impairment progression in AD and with amyloid burden75,76, and given the results of the present study, 
we believe that more investigations on the role of ferritin in AD progression are needed.
We did not find higher concentrations of magnetite/maghemite in the brain region investigated by us (middle 
temporal lobe). However, we did observe larger magnetic moments which suggest that magnetite/maghemite 
particles found in the AD tissue are larger than those found in controls (see Fig. 4). To explain higher magnetite 
levels, it was hypothesized that biogenic magnetite could originate from malfunctioning ferritin9,14,16, and more 
recently, Aβ was shown to mediate the formation of magnetite from ferrihydrite in vitro10. However, a few recent 
studies show that Aβ is able to catalise magnetite formation, even in absence of ferritin, under non-physiological 
pH conditions77. Additionally, Maher et al.78 reported that some of these magnetite particles, which were found in 
the frontal cortex, had a characteristic spherical, rather than cubic, geometry and shared a striking resemblance 
to anthropogenic, combustion-derived magnetite nanoparticles. Leaving aside the origin of these anthropogenic/
biogenic nanoparticles, our results suggest that the size of these magnetite particles is different in presence of AD 
when compared to the control case.
The elevated ⁎R2  values in the AD subjects could be caused by an increase of cortical iron, as suggested by pre-
vious ex vivo79 and in vivo80 observations, where cortical tissue was studied with the same ⁎R2 -weighted pulse 
sequence. Indeed, QSM suggests that an increase in the susceptibility of the neocortex is associated with local iron 
accumulation28,81,82, possibly increasing with the disease staging. Additionally, a significant correlation was found 
between MRI pixel intensity, iron and myelin25. However in the present study, we did not observe a correlation 
between the ⁎R2 values and any assessed iron form. This may be due to the small dynamic range of iron concentra-
tion within the temporal cortex, which can affect the Spearman’s correlation coefficient, or to the difference in the 
spatial resolution of the different techniques (see Materials and Methods). An ⁎R2 increase may also originate from 
susceptibility changes occurring in tissue lesions, i.e. Aβ and τ-tangles83, as pointed out by the trend between ⁎R2  
and Braak Stage shown in Fig. 2, or be caused by microhemorrhages, or myelin changes36,38 also taking place in 
AD25.
Finally, our correlation study (see Table 2) indicates that the Fe(III)-form quantified by EPR is not ‘unspe-
cific’, but it is most likely associated with the iron loading of ferritin. This finding suggests that the EPR-detected 
iron could originate from the iron pool on the outer-surface of the ferrihydrite mineral, as suggested above. 
Additionally, the surprising negative correlation between ferrihydrite concentration and the FLR may be under-
stood in a scenario in which, when the cytoplasmic iron pool increases, ferritin over-expression is initiated as 
a protective mechanism6. This can start a process in which iron is rapidly taken up by newly expressed ferri-
tins, thus resulting in a heterogeneous FLR, and in ferritins which are on average less-filled than those found 
Fe(III) Ferrihydrite FLR
Fe(III) 1 −0.033 0.700
p-value 0 0.852 3.453 • 10−5 (***)
Ferrihydrite 1 −0.464
p-value 0 1.279 • 10−2 (*)
FLR 1
p-value 0
Table 2. Result of the partial correlation test. The partial correlation coefficient is reported together with the 
p-value of the test. AD and control groups have been pooled. The asterisk (*) indicates that the p-value is less 
than 0.05 while the triple asterisk (***) indicates that p < 0.001.
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under normal iron levels. Ultimately, the moderate correlation between magnetite/maghemite and ferrihydrite is 
intriguing and deserves future investigation.
In this work, the temporal cortex of AD patients (N = 22) and control subjects (N = 14) was investigated to 
study the different molecular forms and magnetic properties of iron. An indirect assessment of the iron concen-
tration was performed by measuring the ⁎R2 in the gray matter. The same region was also investigated by EPR and 
SQUID magnetometry and the concentration of non-heme rhombic Fe(III), magnetite/maghemite and ferrihy-
drite, and their respective magnetic moments were derived. Statistical analysis revealed that ⁎R2 values, ferrihy-
drite levels, and magnetite/maghemite magnetic moment are elevated in the temporal cortex of AD patients. This 
suggests a local accumulation of iron and an interaction between magnetite and, possibly Aβ in vivo, in agree-
ment with previous studies.
The correlation study of the measured iron forms indicates that Fe(III) strongly correlates with the amount of 
iron stored within ferritin, and the negative associations between ferrihydrite and the FLR could be interpreted as 
a result of heterogeneously-loaded ferritins, possibly due to ferritin over-expression, to cope with iron overload.
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